Development of a Clinico-biological Database for Patients Receiving Metabolic Radiotherapy
in the Nuclear Medicine Department to Support Cancer Research
Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2026-09-15
350
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are developing a clinico-biological database for patients treated with metabolic radiotherapy in the Nuclear Medicine Department. This study includes patients with thyroid cancer, prostate cancer, neuroendocrine tumors, and somatostatin receptor SSTR positive tumors such as meningiomas. The database aims to provide clinical data and biological materials to the medical and scientific community to better understand the effects of targeted radionuclide therapy TRT on tumors and normal tissues, as well as psycho-oncological mechanisms in treated patients.
The study collects biological samples, primarily blood taken before and during treatment, alongside standardized clinical data entered into the database. An ancillary study called IMMUNORIV is associated with this project, focusing on immune cell profiling in metastatic thyroid cancer and neuroendocrine tumor patients. This includes archiving tumor samples and collecting dosimetric data and additional blood samples during the first treatment cycle to study correlations with treatment response.
Participants provide informed consent and contribute clinical and biological data during their metabolic radiotherapy treatment. Researchers monitor immune responses and treatment effects using the collected biological samples and dosimetric imaging. The primary outcome measure is the proportion of patients consenting to participate, tracked until study completion in 2029. This work supports future research to identify biomarkers and optimize TRT for cancer patients.
CONDITIONS
Brief Title
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Research Team
A
Aurore MOUSSION
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Treated with metabolic radiotherapy in the Nuclear Medicine Department
Diagnosed with thyroid cancer, neuroendocrine tumor or any SSTR positive tumor like meningioma receiving PRRT, or prostate cancer
Agreed to provide additional blood samples
Provided informed, written, and express consent
You will not qualify if you...
Not affiliated with a social security scheme
Under legal protection such as tutelage, curatorship, or safeguard of justice
In an emergency medical situation
Unable to participate in regular monitoring due to psychological, family, social, or geographical reasons
Pregnant or breastfeeding women
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Data and Biological Sample Collection
Duration - Duration of treatment period
Participants provide blood samples before and during metabolic radiotherapy treatment. Clinical data are collected and entered into the database. Some participants with thyroid cancer or neuroendocrine tumors may also provide tumor tissue samples and additional blood samples during treatment cycles.
Visits as scheduled with treatment cycles
Follow-up and Data Analysis
Duration - Until study completion in 2029
Researchers analyze collected clinical and biological data to study treatment effects and identify biomarkers related to immune response and therapy outcomes.
Periodic assessments as needed
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Study of 177Lu-DOTATOC Therapy in Patients With SSTR-Positive Neuroendocrine and Other Related Tumors
Phase I Study of 177Lu-CTR-FAPI Radioligand Therapy for Thyroid Cancer Evaluating Safety and Effectiveness
Study of Lutetium-177 DOTATATE Dosage Based on Individualized Imaging for Treating Adults with Neuroendocrine Tumors
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Safety and Effectiveness of a New 18F Labeled Fibroblast Activation Protein Probe for Early Tumor Detection
Including Lung, Pancreatic, Neuroendocrine, and Thyroid Cancers
Phase III Study of 18F-DOPA PETCT Imaging Optimization Using New Digital Scanner and Furosemide in Pediatric and Adult Patients with Neuroendocrine and Brain Tumors, Parkinsons, and Congenital Hyperinsulinism
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.
Philipp E Hartrampf, Heribert Hänscheid, Olivia Kertels...
[Evaluation of the anxiety state in patients receiving radioiodine treatment or who undergo a sentinel lymph node examination in the Nuclear Medicine Department].
Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies.
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial.
The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma.
No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium.
Giuseppe De Vincentis, Viviana Frantellizzi, Giulia Anna Follacchio...